menu

References

  • 1. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214–20.
  • 2. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419–23.
  • 3. Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al, for the Systemic Lupus International Collaborating Clinics. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 2007;56:265–73.
  • 4. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
  • 5. Omdal R, Jorde R, Mellgren SI, Husby G. Autonomic function in systemic lupus erythematosus. Lupus 1994;3:413-7.
  • 6. Laganá B, Tubani L, Maffeo N, Vella C, Makk E, Baratta L, et al. Heart rate variability and cardiac autonomic function in systemic lupus erythematosus. Lupus. 1996;5:49-55.
  • 7. Gamez-Nava JI, Gonzalez-Lopez L, Ramos-Remus C, Fonseca-Gomez MM, Cardona-Muñoz EG, Suarez-Almazor ME. Autonomic dysfunction in patients with systemic lupus erythematosus. J Rheumatol 1998;25:1092-6.
  • 8. McCombe PA, McLeod JG, Pollard JD, Guo YP, Ingall TJ. Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Clinical, pathological and immunological features. Brain 1987;110:533-49.
  • 9. Young RR, Asbury AK, Adams RD, Corbett JL. Pure pan-dysautonomia with recovery. Trans Am Neurol Assoc 1969;94:355-7.
  • 10. Young RR, Asbury AK, Corbett JL, Adams RD. Pure pan-dysautonomia with recovery. Description and discussion of diagnostic criteria. Brain 1975;98:613-36.
  • 11. Suarez GA, Fealey RD, Camilleri M, Low PA. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology 1994;44:1675-82.
  • 12. Stoll G, Thomas C, Reiners K, Schober R, Hartung HP. Encephalo-myelo-radiculo-ganglionitis presenting as pandysautonomia. Neurology 1991;41:723-6.
  • 13. American College of Rheumatology: Arthritis & Rheumatism. http://www.rheumatology.org/publications/ar/1999/aprilappendix.asp(1999).
  • 14. Hoyle C, Ewing DJ, Parker AC. Acute autonomic neuropathy in association with systemic lupus erythematosus. Ann Rheum Dis 1985;44:420-4.
  • 15. Arruda WO, Teive HA, Ramina R, Wunder PR, Rocha LC. Autonomic neuropathy in systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1989;52:539-40.
  • 16. Jodo S, Sagawa A, Ogura N, Atsumi T, Amasaki Y, Nakabayashi T, et al. A case of systemic lupus erythematosus (SLE) developing pan-dysautonomia. Ryumachi 1992;32:58-65. Japanese.
  • 17. Law WG, Thong BY, Lian TY, Kong KO, Chng HH. Acute pan-dysautonomia: a rare initial presentation of lupus with Sjögren’s syndrome. Lupus 2006;15:899-900.
  • 18. Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve 2003;27:646-61.
  • 19. Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 1998;50:1806-13.
  • 20. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343:847-55.
  • 21. Kusunoki S. Antiglycolipid antibodies in Guillain-Barré syndrome and autoimmune neuropathies. Am J Med Sci 2000;319:234-9.
  • 22. Kusunoki S, Morita D, Ohminami S, Hitoshi S, Kanazawa I. Binding of immunoglobulin G antibodies in Guillain-Barré syndrome sera to a mixture of GM1 and a phospholipid: possible clinical implications. Muscle Nerve 2003;27:302-6.
  • 23. Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, Hirakawa M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 2004;56:567-71.
  • 24. DeGiorgio L, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine 2001;7:1189-1193.
  • 25. Sakic B, Kirkham DL, Ballok DA, et al. Proliferating brain cells a target of neurotoxic CSF insystemic autoimmune disease. J Neuroimmunology 2005;169:68-85.
  • 26. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006;33:1553-8.
  • 27. Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006;54:2505-14.
 

Acknowledgment
All of the authors confirm that there is no conflict of interest with regard to this work.

Fig. 1
Abdominal X-ray/CT on admission. The intestine and colon were markedly dilated, and paralytic ileus was diagnosed.

Fig. 2
a-c Hepatobiliary scintigraphy before IVCY. RI excretion from the liver parenchyma was markedly reduced. Gallbladder ejection fraction (GBEF) 30: 4%, showing a marked reduction (normal: 40% or higher)
d-f Hepatobiliary scintigraphy after IVCY. RI was excreted from the liver parenchyma. GBEF30: 40%, showing improvement

Fig. 3
Clinical Course.
PSL, prednisolone; mPSL, methylprednisolone; IVCY, intravenous cychlophosphamide; PE, plasma exchange

Table 1
Reported cases of SLE with pan-dysautonomia.
PSL, prednisolone; mPSL, methylprednisolone; IVCY, intravenous; AZA, azathioprine; HCQ, hydroxychloroquine; N.S, not showed